[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diet-interventions\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diet-interventions":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,43,72,100,121,154,178,206],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644522","tailored-anti-inflammatory-american-diet-for-patients-with-crohns-disease-100644522",false,"NCT07671872","Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease","Targeting Gut Inflammation Through Diet: a Tailored American Diet for Patients With Crohn's Disease","Inclusion Criteria:\n\n* Documented diagnosis with Crohn's Disease from medical records.\n* Ages 16-75\n* Mild to moderately active CD disease, defined by one of the following criteria:\n\nCrohn's disease activity index (CDAI) 150-250 (mild-to-moderate only active disease) AND presence of active inflammation either by: fecal calprotectin \\>150mg\u002Fdl. or radiologic findings of active ileal and\u002For colonic disease, or endoscopic findings showing active ileal and\u002For colonic disease within 4 weeks of baseline\n\n-On stable medications for their disease as or 3 months if medication is not listed\n\nExclusion Criteria:\n\n* Diagnosis of Ulcerative Colitis (UC).\n* Prior J pouch or diversion\n* Recent inflammatory bowel disease (IBD) related hospitalizations in the last 4 weeks\n* Clostridium difficile or enteric infections in the last 4 weeks\n* Use of probiotics in the last 4 weeks\n* Patients following the specific carbohydrate diet or Mediterranean diet or anti-inflammatory diet\n* Active cancer or conditions limiting their ability to follow a diet (heart failure, end stage renal disease)\n* Pregnancy, breastfeeding or planning to become pregnant during study period\n* Use of Total Parenteral Nutrition at the time of screening and during the study period\n* Other significant or life-threatening co-morbidities\n* The need for antibiotic use during the study period\n* Adults unable to consent\n* Ages \\\u003C 16 and \\> 75 years old\n* Prisoners\n* Crohn's specific complicated disease including active Stenotic (stricturing, B2) disease within the past 12 months, or Internal penetrating (B3) disease, or Draining perianal fistula, or Prior bowel resection\n* Patients with concomitant Celiac disease","ALL","16 Years","75 Years",{"count":20,"type":21},122,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to test the effect of an anti-inflammatory diet tailored for patients living in the United States with Crohn's Disease (CD) on clinical symptoms and disease inflammation and to identify biomarkers of response to dietary therapy.",[27,28,29],"Crohn's Disease, Active","Crohn's Disease (CD)","Diet Interventions","NOT_YET_RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-26","ACTUAL",{"date":36,"type":21},"2026-08",{"date":38,"type":21},"2030-08",{"name":40,"class":41},"University of Miami","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":65,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":42},"100609776","ripe-for-revival-outcomes-evaluation-of-a-mobile-produce-market-with-vouchers-100609776","NCT07218978","Ripe for Revival: Outcomes Evaluation of a Mobile Produce Market With Vouchers","Inclusion Criteria:\n\n* 18 years of age or older\n* Communicates fluently in English or Spanish\n* An active participant in an NC Cooperative Extension program May 2026 - March 2028\n* At risk of food insecurity\n* Willing to shop at or visit a Ripe for Revival mobile produce market\n* Willing to use the provided $20 monthly voucher to shop at the Ripe for Revival mobile produce market\n* Works or lives in a North Carolina county where this study is being conducted, including Bertie, Halifax, Hertford, Jones, Lenoir, Northampton, Warren, or Washington\n\nExclusion Criteria:\n\n* Individuals who do not meet the inclusion criteria above cannot participate","18 Years",{"count":51,"type":21},150,[24],"Increasing access to healthy foods is crucial to combating chronic disease in rural communities. The Ripe for Revival mobile market, a non-profit eastern NC-based mobile market, seeks to improve healthy food access among those at greatest risk of food insecurity and poor health. By implementing vouchers at the mobile market, this study will help make healthy food affordable and accessible. This project is poised to improve diet and health among rural residents in eight counties and promote sustainable local food systems in North Carolina.",[29,55,56,57],"Food Security","Nutrition Security","Fruit and Vegetable Intake",[59,60,57,61,62,63],"Mobile market","Lower-income","Quasi-Experimental","Vouchers","Nutrition Incentives","RECRUITING",{"date":33,"type":34},{"date":67,"type":34},"2026-05-01",{"date":69,"type":21},"2028-03-31",{"name":71,"class":41},"North Carolina State University",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":42},"100643424","health-effects-of-ultra-processed-food-intake-100643424","NCT07634159","Health Effects of Ultra-processed Food Intake","Health Effects of Ultra-processed Food Intake: a Randomized Crossover Feeding Study","UPFront","Inclusion Criteria:\n\n* Age 20-60 years\n* Weight stable (less than 5% weight change in the past 3 months)\n* No plans to change weight\n* Willing to eat the study diet and a mixed diet\n* Has provided informed consent to participate in the study\n\nExclusion Criteria:\n\n* Allergy or intolerance to foods included in the study. Participants with lactose intolerance treated with lactase may participate if they take enzymes.\n* BMI \\\u003C18.5 or \\>35 kg\u002Fm²\n* Use of medications known to significantly affect appetite (e.g., oral corticosteroids, antipsychotic medications, or GLP-1 receptor agonists)\n* Use of lipid-lowering medications (e.g., statins or PCSK9 inhibitors)\n* Diagnosed diabetes or capillary blood glucose at or above 12.2 mmol\u002FL\n* Disease associated with malabsorption (e.g., inflammatory bowel disease or celiac disease)\n* Previous bariatric surgery\n* Established cardiovascular disease (heart failure, myocardial infarction, or stroke) or cancer\n* Pregnancy or breastfeeding, or plans to become pregnant or breastfeed during the study",true,"20 Years","60 Years",{"count":84,"type":21},40,[24],"Ultra-processed food (UPF) intake has been related to negative health effects and incresed energy intake in previous intervention studies. Thus, previous studies have seen weight gain from higher UPF intake which obscures the potentital to see effects on cardiometabolic biomarkers, independent of weight changes. The overall aim of this project is to study the causal effects of a high UPF diet, compared to a nutrient-matched low UPF diet, on appetite and cardiometabolic health in a weight-stable context.",[88,89,29],"Cardiometabolic Risk Factors","Microbiota",[91],"Ultra-processed food","2026-06-03",{"date":94,"type":34},"2026-06-08",{"date":36,"type":21},{"date":97,"type":21},"2027-12",{"name":99,"class":41},"Göteborg University",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":80,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":119,"locationsCount":42},"100619544","impacts-of-sugar-warnings-on-weight-bias-100619544","NCT07346001","Impacts of Sugar Warnings on Weight Bias","Impacts of Prolonged Exposure to Added Sugar Warning Labels on Explicit Weight Bias: a Randomized Controlled Trial","Inclusion Criteria:\n\n* 18 years and older\n* Bought sugary drinks from a store at least once during the past week\n* Willing to attend 4 in-person study appointments\n\nExclusion Criteria:\n\n• Living in the same household as someone else in the study",{"count":108,"type":21},543,[24],"This study aims to examine the effects of added sugar warning labels for sugar-sweetened beverages (SSBs) on explicit weight bias and body weight attributional judgements. Participants will be assigned to view either control labels or added sugar warning labels applied on SSBs in an experimental store. Participants will shop for beverages in the store and take a computer survey during four visits to the store, spaced approximately one week apart.",[112,29],"Nutrition","2026-04-14",{"date":115,"type":34},"2026-04-16",{"date":117,"type":34},"2026-02-16",{"date":97,"type":21},{"name":120,"class":41},"University of North Carolina, Chapel Hill",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":16,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":141,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":42},"100630132","multimodal-intervention-for-early-chronic-kidney-disease-in-young-people-dysbiosis-and-inflammation-ckd-100630132","NCT07483697","Multimodal Intervention for Early Chronic Kidney Disease in Young People: Dysbiosis and Inflammation (CKD)","Multimodal Intervention and Its Association With Reduced Dysbiosis and Inflammation in Early Chronic Kidney Disease in Young People: a Prospective Study","CKD","Inclusion Criteria:\n\n* Persistent albuminuria (ACR \\>30 and \\\u003C300 mg\u002Fg).\n* Estimated GFR \\>60 mL\u002Fmin\u002F1.73 m².\n* No identifiable secondary cause of kidney disease.\n\nExclusion Criteria:\n\n* Hypoalbuminemia.\n* Nephrotic syndrome.\n* Persistent macroalbuminuria (ACR \\>300 mg\u002Fg).\n* Secondary or hereditary kidney disease.","14 Years","35 Years",{"count":132,"type":21},200,[24],"Chronic kidney disease (CKD) is a progressive condition associated with substantial morbidity, mortality, and healthcare costs. Early detection and timely intervention are critical to modify disease trajectory, particularly in adolescents and young adults. Emerging evidence supports the role of the gut-kidney axis in CKD progression, whereby intestinal dysbiosis contributes to systemic inflammation and accumulation of microbiota-derived uremic toxins. This randomized controlled clinical trial aims to evaluate whether a multimodal intervention consisting of a controlled diet, structured exercise, and a symbiotic administered for 180 days improves uremic toxin burden, systemic inflammation, and early renal outcomes compared with standard care plus placebo.",[136,29,137,138,139,140],"Exercise","Symbiotic","CKD Stage 1","CKD Stage 3","CKD Stage 2",[127,142,143,144],"exercise","symbiotic","diet","2026-03-17",{"date":147,"type":34},"2026-03-19",{"date":149,"type":21},"2026-04-25",{"date":151,"type":21},"2026-11-03",{"name":153,"class":41},"Centenario Hospital Miguel Hidalgo",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":80,"sex":16,"minAge":49,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":42},"100603576","dietary-impact-on-sleep-rhythms-and-related-physiology-100603576","NCT07138313","Dietary Impact on Sleep, Rhythms and Related Physiology","Inverkan av Kost pa Dygnsrytmer Och Amnesomsattning","Inclusion Criteria:\n\n* Age 18-32 yr\n* Healthy (self-reported) and not on chronic medication\n* BMI 18-27 kg\u002Fm2 (and waist circumference \\\u003C102 cm), and weight stable (less than 5% body weight change in the past 6 months)\n* Non-smoker and non-nicotine user\n* Regular sleep-wake pattern, with sleep duration of 7-9.25 hrs per night\n* Regular exercise habits the last 2 months\n* Regular daily meal pattern with 3 main meals\n\nExclusion Criteria:\n\n* Major or chronic illness, e.g. diabetes, renal disease or inflammatory bowel disease\n* Current or history of endocrine or metabolic disorders\n* Psychiatric or neurological disorders (e.g. bipolar disorder, epilepsy)\n* Frequent gastrointestinal symptoms\n* Chronic medication\n* Any sleep disorder (including recent or chronic symptoms of insomnia)\n* Shift work in the preceding three months or for a long duration\n* Extreme chronotype or physical activity patterns\n* Time travel over two time zones in the preceding month\n* Too much weight gain or weight loss in the preceding 6 months (±5% body weight in past 6 months)\n* Any issues with or allergies against the provided food items\n* Recent major dietary changes or adoption of specific dietary regimens\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the study period.\n* Use of illicit drugs or substances of abuse","32 Years",{"count":163,"type":21},24,[24],"Sleep and metabolism are closely interconnected, and emerging evidence suggests that dietary composition may influence both sleep quality and key physiological functions such as glucose regulation, cardiovascular activity, and hormonal signaling. This study aims to investigate how a Western-style unhealthy diet versus a healthier, fiber-rich diet affects objective and subjective sleep measures, 24-hour physiological parameters, and a range of biomarkers related to cardiometabolic, neurodegenerative, and gut microbial function.",[167,29,168],"Sleep","Circadian Rhythm","2026-02-03",{"date":171,"type":34},"2026-02-04",{"date":173,"type":34},"2025-09-22",{"date":175,"type":21},"2027-12-31",{"name":177,"class":41},"Uppsala University",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":4,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":185,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":188,"briefSummary":189,"conditions":190,"keywords":195,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":197,"lastUpdatePostDateStruct":198,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":42},"100604666","the-resistant-starch-intervention-for-cognitive-enhancement-100604666","NCT07152483","The Resistant Starch Intervention for Cognitive Enhancement","The Resistant Starch Intervention for Cognitive Enhancement (RICE) in Individuals With High Genetic Risk","Inclusion Criteria:\n\n* Patients aged ≥ 40 years\n* meta-polygenic risk score (metaPRS) \\> 0.4\n* Montreal Cognitive Assessment (MoCA) score ≤ 26\n* Central obesity (waist circumference \\> 90 cm in males or \\> 80 cm in females) or body mass index (BMI) ≥ 28 kg\u002Fm²\n* Written informed consent available\n* Proficient in using smartphones\n* Willingness to complete all assessments and participate in follow-up\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to resistant starch\n* previously diagnosed dementia\n* Suspected dementia after clinical assessment by study physician at screening visit\n* Previous history of major head trauma and any intracranial surgery\n* Intracranial abnormalities, such as intracerebral hemorrhage, subarachnoid hemorrhage and other space occupying lesions\n* Extrapyramidal symptoms or mental illness which may affect neuropsychological measurement\n* Severe loss of vision, hearing, or communicative ability\n* Patients presenting a malignant disease with life expectancy \\\u003C 3 years\n* Participation in an ongoing investigational drug study\n* The participant or a first-degree relative is currently participating in another clinical trial involving nutritional intervention.\n\nExit Criteria:\n\n* Not meet the inclusion criteria\n* For any poor adherence, not comply with the requirements of the follow-up, or safety reasons determined by investigator\n* Any adverse or serious adverse events during the study period judged by Investigator","40 Years",{"count":187,"type":21},70,[24],"The investigation will explore the potential effects of resistant starch The Resistant Starch Intervention for Cognitive Enhancement study aimed to evaluate the effect of high-resistant starch diet intervention in slowing cognitive decline among individuals at high genetic risk for cognitive impairment. Participants will be randomly assigned to either an intervention group receiving daily high-resistant starch food products or a control group receiving isoenergetic regular starch products. The investigation will validate the potential effects of resistant starch on cognitive function protection and explore the underlying mechanisms through comprehensive data collection, including standardized neuropsychological assessments, laboratory biomarkers derived from blood and fecal specimens, and multimodal magnetic resonance imaging.",[191,29,192,193,194],"Cognitive Impairment","Cognitive Decline","Genetic Risk Factors","Obesity &Amp; Overweight",[191,29,192,193,196],"Obesity & Overweight","2025-08-26",{"date":199,"type":34},"2025-09-03",{"date":201,"type":21},"2025-09-01",{"date":203,"type":21},"2026-12-01",{"name":205,"class":41},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":210,"acronym":211,"eligibilityCriteria":212,"healthyVolunteers":80,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":216,"conditions":217,"keywords":218,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":230},"100574402","the-triad-of-nutrition-intestinal-microbiota-and-rheumatoid-arthritis-tasty-100574402","NCT06758817","The Triad of Nutrition, Intestinal Microbiota and Rheumatoid Arthritis (TASTY)","TASTY","Inclusion Criteria:\n\n* RA patients (ACR\u002FEULAR2010 criteria)\n* Age \\>18-years\n* Disease duration \\>1-year\n* Active disease (DAS28 \\> 2.6units)\n* On stable medication for 12 weeks\n* Low\u002Fmedium MedDiet adherence (PREDIMED\\\u003C10)\n* Willing to comply with study protocol\n\nExclusion Criteria:\n\n* Prednisolone dose ≥ 7.5 mg\u002Fday\n* Antibiotic therapy 4-weeks prior to baseline\n* Persistent use of NSAID's\n* Inflammatory or irritable bowel disease\n* Celiac disease\n* Chronic diarrhea\n* Diabetes\n* Other immune-mediated inflammatory diseases besides RA\n* Major organ dysfunction\n* Cancer diagnosed in the last five years\n* Health conditions which may difficult participation (cognitive impairment\u002Fpsychiatric disease)\n* Pregnant or lactating individuals",{"count":214,"type":21},100,[24],"The main goal of this trial is to investigate whether a dietary intervention based on a typical Mediterranean Diet enriched with fermented foods (MedDiet+) can impact gut microbiota and RA-related outcomes.",[29],[29,219],"rheumatoid arthritis","2024-12-27",{"date":222,"type":34},"2025-01-06",{"date":224,"type":34},"2023-01-02",{"date":226,"type":21},"2025-12-31",{"name":228,"class":229},"Lisbon Academic Medical Center - Centro Académico de Medicina de Lisboa","NETWORK",2]